logo-loader

BioVie to present Long COVID trial data at NIH-backed workshop

Last updated: 03:39 27 Oct 2026 AEDT, First published: 00:39 27 Oct 2026 AEDT

BioVie Inc - BioVie to present Long COVID trial data at NIH-backed workshop

BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) has been invited to present results from its Phase 2 ADDRESS-LC trial of investigational drug bezisterim at a US government-backed workshop focused on accelerating treatments for Long COVID. 

The clinical-stage biopharmaceutical company, which develops therapies for neurological and neurodegenerative diseases, will present the findings at the 2026 RECOVER-TLC Hybrid Workshop in Bethesda, Maryland. 

Dr Penelope Markham, BioVie’s senior vice president and Long COVID program lead, will discuss the results in a panel titled “Recent Insights from Long COVID Clinical Trials” on November 5.  

The event is hosted by the National Institute of Allergy and Infectious Diseases and the Foundation for the National Institutes of Health. 

The ADDRESS-LC study showed a consistent trend toward improvement with bezisterim across most patient-reported and objective efficacy measures compared with placebo, according to BioVie. 

Patients with more severe fatigue, post-exertional malaise or measurable cognitive impairment at the start of the study appeared to benefit most. These symptoms affected about 78% of participants in at least one of the three domains, with statistically significant improvements reported across multiple measures associated with their most pronounced symptoms. 

Safety and tolerability were similar between patients receiving bezisterim and those given placebo. 

“We observed a consistent and clinically coherent pattern of improvement across measures of fatigue, post-exertional malaise, clinician- and patient-reported outcomes, and objective measures of cognitive function among patients with greater baseline symptom burden,” Markham said. 

She said the findings could help identify patients most likely to benefit from treatment and inform the design of a confirmatory Phase 3 trial. 

The randomized, placebo-controlled ADDRESS-LC study enrolled about 200 adults with Long COVID who experienced cognitive impairment and fatigue. Participants received either 20 milligrams of oral bezisterim twice daily or a matching placebo. 

The signal-finding trial evaluated 22 clinical outcome measures and was fully funded through a US$13.13 million grant from the US Department of War. 

The RECOVER-TLC Initiative aims to accelerate the development of treatments for Long COVID, for which no therapies have yet been approved. The initiative has advanced four therapeutic candidates into clinical testing. 

Bezisterim is an investigational oral drug designed to cross the blood-brain barrier, reduce inflammation and improve insulin sensitivity without suppressing the immune system. Its potential use in Long COVID remains under investigation, and further clinical testing will be needed to establish its safety and efficacy. 

Shares of BioVie gained 8.1% on Monday morning at $1.34.

XanaMIA results: What's next for Actinogen Medical?

Actinogen Medical Ltd CEO Dr Steven Gourlay talked with Proactive about the topline results from the company's XanaMIA clinical trial, which evaluated its investigational Alzheimer's disease treatment Xanamem. The study revealed encouraging signs of disease slowing in patients aged...

10 hours, 54 minutes ago